 RTT News |
GlaxoSmithKline Boosts Stake In Theravance To 27%
NASDAQ The move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a … GlaxoSmithKline to Increase Its Ownership in Theravance GlaxoSmithKline invests $213M in Theravance Inc. Glaxo Lifts Theravance Stake |
View full post on asthma – Google News